Caimi Paolo F, Hill Brian T, Hsi Eric D, Smith Mitchell R
Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, OH, USA.
Blood Rev. 2016 Nov;30(6):477-491. doi: 10.1016/j.blre.2016.06.003. Epub 2016 Jun 30.
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of lymphoma. We now recognize that DLBCL corresponds to a biologically heterogeneous family of diseases. Given the potential for cure for most DLBCL patients, appropriate diagnostic and staging evaluation and therapy are essential. Here we review areas of consensus as well as controversy in the evaluation, treatment and monitoring of patients with DLBCL and its related subtypes.
弥漫性大B细胞淋巴瘤（DLBCL）是淋巴瘤最常见的亚型。我们现在认识到，DLBCL对应于一组生物学上异质性的疾病。鉴于大多数DLBCL患者有治愈的可能，适当的诊断、分期评估和治疗至关重要。在此，我们回顾了DLBCL及其相关亚型患者评估、治疗和监测方面的共识及争议领域。
